Order Both Apolipoprotein B and Apolipoprotein A-I
For comprehensive cardiovascular risk assessment, measure both apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I), with apoB being the single most important marker for atherogenic risk. If you must choose only one test, order apoB, as it directly quantifies the number of atherogenic lipoprotein particles and is superior to LDL cholesterol for predicting cardiovascular events 1, 2.
Why Both Tests Matter
Apolipoprotein B (The Priority Test)
- ApoB measures the total number of atherogenic particles (VLDL, LDL, IDL, and Lp(a)) because each particle contains exactly one apoB molecule 3, 4
- ApoB is superior to LDL-C for risk prediction, particularly when discordant with LDL cholesterol 1, 5, 6
- Even 2% discordance between apoB and LDL particle number significantly increases cardiovascular risk (HR 1.1 for both MACE and CAD, P<0.0001), with risk escalating to HR 2.5 for CAD at 30% discordance 1
- Excess apoB above expected levels from LDL-C alone shows dose-dependent increased risk: HR 1.75 for ASCVD in women and HR 1.52 in men when excess apoB >100 mg/dL 2
Apolipoprotein A-I (The Protective Marker)
- ApoA-I is the major protein in HDL particles and inversely correlates with cardiovascular risk 7, 3
- High apoA-I levels are protective against coronary disease 7
The ApoB/ApoA-I Ratio (The Optimal Risk Predictor)
The apoB/apoA-I ratio outperforms all cholesterol-based ratios (TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C) for predicting coronary risk 8, 7, 3. This ratio:
- Combines atherogenic burden (apoB) with protective factors (apoA-I)
- Shows superior predictive value especially in patients with LDL-C <3.6 mmol/L (139 mg/dL) 7
- Adding any cholesterol measurements to the apoB/apoA-I ratio does not improve its predictive power 7
Clinical Scenarios Where ApoB Testing Is Critical
When ApoB Reveals Hidden Risk (Common Pitfall)
Patients with metabolic syndrome, obesity, or type 2 diabetes frequently have:
- Normal or near-normal LDL-C levels
- Elevated apoB (indicating increased atherogenic particle number)
- This discordance means LDL-C underestimates their true cardiovascular risk 9, 6
Practical Testing Algorithm
- Initial assessment: Order apoB, apoA-I, and standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
- Calculate apoB/apoA-I ratio: Higher ratio = higher risk 8, 7
- Identify discordance: If apoB is elevated despite acceptable LDL-C, the patient has more atherogenic particles than LDL-C suggests 1, 2
- Treatment target: Aim for apoB <90 mg/dL in high-risk patients, though <80 mg/dL may be considered for ultra-high-risk patients 3
Key Advantages Over Standard Cholesterol Testing
- Standardized measurement: ApoB assays are standardized; LDL-C and non-HDL-C measurements are not 5, 6
- No fasting required: Unlike triglycerides and calculated LDL-C 7
- Better treatment monitoring: ApoB more accurately reflects adequacy of statin therapy than LDL-C 7, 3
- Phenotype identification: Combined with lipid panel, apoB/apoA-I helps distinguish specific lipoprotein disorders 5, 6
Important Caveat
While the 2013 ACC/AHA guidelines acknowledge apoB in their abbreviations list, they have not formally incorporated apoB into primary risk assessment algorithms 10. However, the evidence strongly supports that apoB provides superior risk stratification, particularly for intermediate-risk patients where traditional risk calculators perform poorly 8. The National Lipid Association's 2024 Expert Consensus explicitly endorses apoB measurement for clinical care 6.
Bottom line: Order both apoB and apoA-I when available, calculate the ratio, and use apoB as your primary marker for atherogenic burden and treatment targets. This approach identifies high-risk patients missed by LDL-C alone and provides more accurate cardiovascular risk assessment across all patient populations.